Real-Time PMA Supplements Should Include Risk Analysis, FDA Says
This article was originally published in The Gray Sheet
Executive Summary
Real-time PMA supplements should include a detailed risk analysis to support the continued safety and effectiveness of the modified device, FDA stresses in a guidance issued April 28
You may also be interested in...
FDA News In Brief
FDA responds to drug-eluting stent concerns: Agency announces public meeting of the Circulatory System Devices Advisory Panel by year-end to address mounting concerns about late stent thrombosis prompted by the release of new data at the European Society of Cardiology/World Congress of Cardiology meeting in Barcelona this month and the American College of Cardiology scientific sessions in Atlanta in March. FDA aims to deepen understanding of late stent thrombosis and gauge correct duration of antiplatelet-drug regimens for drug-eluting stent recipients. Still, FDA stands by the safety and efficacy of the Cypher (J&J/Cordis) and Taxus (Boston Scientific) drug-eluting stents when used for approved indications. Boston Scientific, which recently reported a slightly higher risk of clots for Taxus compared to bare-metal stents, will disclose 48-month results from clinical trials at the Transcatheter Cardiovascular Therapeutics meeting Oct. 22-27 in Washington, D.C....
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.